A Study to Evaluate MRG003 vs Cetuximab/Methotrexate in in the Treatment of Patients With RM-SCCHN
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to compare the efficacy and safety of MRG003 versus
cetuximab/methotrexate as second/third line of therapy in patients with RM-SCCHN who have
previously failed PD-1 (L1) inhibitors and platinum-based therapy.